News & Insights
Stay Informed With Our Latest Updates
Explore our comprehensive collection of news and in-depth insights spanning practice areas, industries, and regions.
Firm News April 2, 2026
Gibson Dunn Advises BVF Partners L.P. on up to $24.5 Million Financing for Entera Bio
Gibson Dunn represented BVF Partners L.P. in its up to $24.5 million private placement financing for Entera Bio Ltd., a clinical stage company focused on developing oral peptide and protein replacement therapies for significant unmet medical needs where an oral tablet form holds the potential to transform the standard of care.
Firm News March 10, 2026
Gibson Dunn Advises Coastlands Capital on up to $30 Million Financing for Longeveron Inc.
Gibson Dunn represented Coastlands Capital as lead investor in the up to $30 million private placement financing for Longeveron Inc., a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions.
Firm News March 9, 2026
Gibson Dunn Advises Coastlands Capital on up to $40 Million Financing for AN2 Therapeutics, Inc.
Gibson Dunn represented Coastlands Capital as lead investor in the up to $40 million private placement financing for AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform.
Client Alert February 26, 2026
California Venture Capital Diversity Reporting Requirements Set To Take Effect
Covered “venture capital companies” must register with the DFPI beginning March 1, 2026, and, by April 1, 2026, must submit …
Firm News February 25, 2026
Gibson Dunn Advises BVF Partners L.P. on up to $400 Million Financing for Immunic, Inc.
Gibson Dunn represented BVF Partners L.P. as lead investor in the up to $400 million private placement financing for Immunic, Inc., a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases.
Webcasts November 20, 2025
Webcast: IPO Readiness Series: Crossover Rounds
Join us for a recorded presentation that provides an overview on crossover rounds leading up to an Initial Public Offering. …
Firm News October 14, 2025
Gibson Dunn Advises KKR on Participation in Series A Financing Round of Expedition Therapeutics
Gibson Dunn advised KKR in connection with its participation in the Series A financing round of Expedition Therapeutics, Inc., an …
Firm News October 9, 2024
Gibson Dunn Advises Fairmount Funds on $110 Million PIPE Transaction for Inhibikase Therapeutics
Gibson, Dunn & Crutcher LLP advised Fairmount Funds on its participation in the $110 million PIPE transaction for Inhibikase Therapeutics.